Atorvastatin can meritoriously improve the quality of life of chronic obstructed pulmonary disorder patients

Dr. Fatima Rizvi; Dr. Syed Mahboob Alam; Dr. Farah Asad

Authors

Dr. Fatima Rizvi Associate Professor Pharmacology, Dow International Medical College (DIMC)
Dr. Syed Mahboob Alam Associate Professor Pharmacology, Basic Medical Science Institute (BMSI)
Dr. Farah Asad Associate Professor Pharmacology, Jinnah Medical and Dental College (JMDC), Pakistan

Keywords:

COPD, SGRQ, QOL, BODE index, Pleiotropic consequences

Abstract

Objective: To demonstrate the impact of Atorvastatin on heath associated quality of life in chronic obstructive pulmonary disease patients.

Methodology: This interventional study carried out in the department of Pharmacology & Therapeutics in alliance with Chest medicine department of JPMC Karachi into 6 months period (December 2011 to May 2012). 85 sufferers with moderate stable COPD, with hsCRP >3mg/lit, had been appraised in this trial. The patients have been allocated to receive Tab. Atorvastatin, for 12 consecutive weeks. The primary efficacy parameters were St. George’s Respiratory Questionnaire (SGRQ) and BODE index.

Results: Out of 85 sufferers most effective 83 (94%) sufferers had been finished the study. The Atorvastatin significantly decreases the all four domains of SGRQ. The mean symptom score was 66.2±1.06 decreases to 54.4±1.31, likewise activity score turned into 51.6 ± 1.35 from 60.4±1.64, impact score changed into 51.6±1.26 from 60.6±0.87 and total score changed into 54.9±0.60 from 61.6 ± 0.73. Atorvastatin had significant impact on improvement of MMRC dyspnea score, spirometric findings and exercise capacity.

Conclusion: This demonstrates that the Atorvastatin effectively enhancing the excellent of existence through having satisfactory impact on the health associated questionnaire of COPD.